The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Macular Degeneration (AMD) and Other Retinal Diseases Market Research Report 2025
Synopsis
Macular degeneration (AMD) and other retinal diseases are mainly related to long-term and chronic light damage in macular area, choroidal vascular sclerosis, and aging of retinal pigment epithelial cells, often including Lucentis, Eylea, Avastin and other brands.
The global Macular Degeneration (AMD) and Other Retinal Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Macular Degeneration (AMD) and Other Retinal Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Macular Degeneration (AMD) and Other Retinal Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Macular Degeneration (AMD) and Other Retinal Diseases in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Macular Degeneration (AMD) and Other Retinal Diseases include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma, Merck, Allergan, Santen Pharmaceutical and GlaxoSmithKline Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Macular Degeneration (AMD) and Other Retinal Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macular Degeneration (AMD) and Other Retinal Diseases.
Report Scope
The Macular Degeneration (AMD) and Other Retinal Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Macular Degeneration (AMD) and Other Retinal Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Macular Degeneration (AMD) and Other Retinal Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Merck
Allergan
Santen Pharmaceutical
GlaxoSmithKline Pharmaceuticals
Pfizer
Acucela
Valent Pharmaceuticals
IVERIC
Segment by Type
Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy(DR)
Retinal Vein Occlusion
Wet Age-Related Macular Degeneration (wAMD)
Dry Age-Related Macular Degeneration (dAMD)
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Macular Degeneration (AMD) and Other Retinal Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Macular degeneration (AMD) and other retinal diseases are mainly related to long-term and chronic light damage in macular area, choroidal vascular sclerosis, and aging of retinal pigment epithelial cells, often including Lucentis, Eylea, Avastin and other brands.
The global Macular Degeneration (AMD) and Other Retinal Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Macular Degeneration (AMD) and Other Retinal Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Macular Degeneration (AMD) and Other Retinal Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Macular Degeneration (AMD) and Other Retinal Diseases in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Macular Degeneration (AMD) and Other Retinal Diseases include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma, Merck, Allergan, Santen Pharmaceutical and GlaxoSmithKline Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Macular Degeneration (AMD) and Other Retinal Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macular Degeneration (AMD) and Other Retinal Diseases.
Report Scope
The Macular Degeneration (AMD) and Other Retinal Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Macular Degeneration (AMD) and Other Retinal Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Macular Degeneration (AMD) and Other Retinal Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Merck
Allergan
Santen Pharmaceutical
GlaxoSmithKline Pharmaceuticals
Pfizer
Acucela
Valent Pharmaceuticals
IVERIC
Segment by Type
Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy(DR)
Retinal Vein Occlusion
Wet Age-Related Macular Degeneration (wAMD)
Dry Age-Related Macular Degeneration (dAMD)
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Macular Degeneration (AMD) and Other Retinal Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Macular Degeneration
1.2.3 Diabetic Macular Edema
1.2.4 Diabetic Retinopathy(DR)
1.2.5 Retinal Vein Occlusion
1.2.6 Wet Age-Related Macular Degeneration (wAMD)
1.2.7 Dry Age-Related Macular Degeneration (dAMD)
1.2.8 Other
1.3 Market by Application
1.3.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Perspective (2019-2030)
2.2 Macular Degeneration (AMD) and Other Retinal Diseases Growth Trends by Region
2.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Region (2019-2024)
2.2.3 Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Region (2025-2030)
2.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Dynamics
2.3.1 Macular Degeneration (AMD) and Other Retinal Diseases Industry Trends
2.3.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers
2.3.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges
2.3.4 Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue
3.1.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue (2019-2024)
3.1.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Players (2019-2024)
3.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Macular Degeneration (AMD) and Other Retinal Diseases Revenue
3.4 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio
3.4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2023
3.5 Macular Degeneration (AMD) and Other Retinal Diseases Key Players Head office and Area Served
3.6 Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service
3.7 Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type
4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Type (2019-2024)
4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2025-2030)
5 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application
5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Application (2019-2024)
5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2019-2030)
6.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2019-2024)
6.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2019-2030)
7.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2019-2024)
7.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2019-2030)
8.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2019-2024)
8.4 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2019-2030)
9.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2019-2024)
9.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2019-2030)
10.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2019-2024)
10.4 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Company Detail
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.1.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.1.5 Regeneron Pharmaceuticals Recent Development
11.2 Bayer HealthCare
11.2.1 Bayer HealthCare Company Detail
11.2.2 Bayer HealthCare Business Overview
11.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.2.4 Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.2.5 Bayer HealthCare Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.3.4 Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.4.4 Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.4.5 Roche Recent Development
11.5 Kanghong Pharma
11.5.1 Kanghong Pharma Company Detail
11.5.2 Kanghong Pharma Business Overview
11.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.5.4 Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.5.5 Kanghong Pharma Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.6.4 Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Allergan
11.7.1 Allergan Company Detail
11.7.2 Allergan Business Overview
11.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.7.4 Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.7.5 Allergan Recent Development
11.8 Santen Pharmaceutical
11.8.1 Santen Pharmaceutical Company Detail
11.8.2 Santen Pharmaceutical Business Overview
11.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.8.4 Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.8.5 Santen Pharmaceutical Recent Development
11.9 GlaxoSmithKline Pharmaceuticals
11.9.1 GlaxoSmithKline Pharmaceuticals Company Detail
11.9.2 GlaxoSmithKline Pharmaceuticals Business Overview
11.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.9.4 GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.9.5 GlaxoSmithKline Pharmaceuticals Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.10.4 Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.10.5 Pfizer Recent Development
11.11 Acucela
11.11.1 Acucela Company Detail
11.11.2 Acucela Business Overview
11.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.11.4 Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.11.5 Acucela Recent Development
11.12 Valent Pharmaceuticals
11.12.1 Valent Pharmaceuticals Company Detail
11.12.2 Valent Pharmaceuticals Business Overview
11.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.12.4 Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.12.5 Valent Pharmaceuticals Recent Development
11.13 IVERIC
11.13.1 IVERIC Company Detail
11.13.2 IVERIC Business Overview
11.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Introduction
11.13.4 IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
11.13.5 IVERIC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Macular Degeneration
Table 3. Key Players of Diabetic Macular Edema
Table 4. Key Players of Diabetic Retinopathy(DR)
Table 5. Key Players of Retinal Vein Occlusion
Table 6. Key Players of Wet Age-Related Macular Degeneration (wAMD)
Table 7. Key Players of Dry Age-Related Macular Degeneration (dAMD)
Table 8. Key Players of Other
Table 9. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2019-2024)
Table 13. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2025-2030)
Table 15. Macular Degeneration (AMD) and Other Retinal Diseases Market Trends
Table 16. Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers
Table 17. Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges
Table 18. Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints
Table 19. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Players (2019-2024)
Table 21. Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration (AMD) and Other Retinal Diseases as of 2023)
Table 22. Ranking of Global Top Macular Degeneration (AMD) and Other Retinal Diseases Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service
Table 26. Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2019-2024)
Table 30. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2025-2030)
Table 32. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2019-2024)
Table 34. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2025-2030)
Table 36. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 51. Regeneron Pharmaceuticals Company Detail
Table 52. Regeneron Pharmaceuticals Business Overview
Table 53. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 54. Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 55. Regeneron Pharmaceuticals Recent Development
Table 56. Bayer HealthCare Company Detail
Table 57. Bayer HealthCare Business Overview
Table 58. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 59. Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 60. Bayer HealthCare Recent Development
Table 61. Novartis Company Detail
Table 62. Novartis Business Overview
Table 63. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 64. Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 65. Novartis Recent Development
Table 66. Roche Company Detail
Table 67. Roche Business Overview
Table 68. Roche Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 69. Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 70. Roche Recent Development
Table 71. Kanghong Pharma Company Detail
Table 72. Kanghong Pharma Business Overview
Table 73. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 74. Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 75. Kanghong Pharma Recent Development
Table 76. Merck Company Detail
Table 77. Merck Business Overview
Table 78. Merck Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 79. Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 80. Merck Recent Development
Table 81. Allergan Company Detail
Table 82. Allergan Business Overview
Table 83. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 84. Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 85. Allergan Recent Development
Table 86. Santen Pharmaceutical Company Detail
Table 87. Santen Pharmaceutical Business Overview
Table 88. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 89. Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 90. Santen Pharmaceutical Recent Development
Table 91. GlaxoSmithKline Pharmaceuticals Company Detail
Table 92. GlaxoSmithKline Pharmaceuticals Business Overview
Table 93. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 94. GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 95. GlaxoSmithKline Pharmaceuticals Recent Development
Table 96. Pfizer Company Detail
Table 97. Pfizer Business Overview
Table 98. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 99. Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 100. Pfizer Recent Development
Table 101. Acucela Company Detail
Table 102. Acucela Business Overview
Table 103. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 104. Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 105. Acucela Recent Development
Table 106. Valent Pharmaceuticals Company Detail
Table 107. Valent Pharmaceuticals Business Overview
Table 108. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 109. Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 110. Valent Pharmaceuticals Recent Development
Table 111. IVERIC Company Detail
Table 112. IVERIC Business Overview
Table 113. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Product
Table 114. IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024) & (US$ Million)
Table 115. IVERIC Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type: 2023 VS 2030
Figure 3. Macular Degeneration Features
Figure 4. Diabetic Macular Edema Features
Figure 5. Diabetic Retinopathy(DR) Features
Figure 6. Retinal Vein Occlusion Features
Figure 7. Wet Age-Related Macular Degeneration (wAMD) Features
Figure 8. Dry Age-Related Macular Degeneration (dAMD) Features
Figure 9. Other Features
Figure 10. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application: 2023 VS 2030
Figure 12. Hospital Case Studies
Figure 13. Clinic Case Studies
Figure 14. Other Case Studies
Figure 15. Macular Degeneration (AMD) and Other Retinal Diseases Report Years Considered
Figure 16. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region: 2023 VS 2030
Figure 19. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Players in 2023
Figure 20. Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration (AMD) and Other Retinal Diseases as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2023
Figure 22. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2019-2030)
Figure 24. United States Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2019-2030)
Figure 28. Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2019-2030)
Figure 36. China Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2019-2030)
Figure 44. Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2019-2030)
Figure 48. Turkey Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Regeneron Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 51. Bayer HealthCare Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 52. Novartis Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 53. Roche Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 54. Kanghong Pharma Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 55. Merck Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 56. Allergan Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 57. Santen Pharmaceutical Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 58. GlaxoSmithKline Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 59. Pfizer Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 60. Acucela Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 61. Valent Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 62. IVERIC Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2019-2024)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
